Twenty-four Year Single-Center Experience of Hepatitis B Virus Infection in Heart Transplantation

Chen, Yee‐Chun; Chuang, Ming Kai; Chou, Nai‐Kuan; H, N; Wu, I-Hui; Chen, Y S; Yu, Hsi‐Yu; Huang, Shang‐Chin; Wang, C H; Tsao, C.-I.; Ko, Wen Je; Wang, S S

doi:10.1016/j.transproceed.2012.03.040

Cited by 26 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited data exist for the use of HBsAg+ donors in heart transplantation. Most available data are published by one group in Taiwan with the apparent inclusion of the same subjects in more than one publication . Of at least 36 reported recipients of HBsAg+ donor hearts, HBsAg acquisition was observed in two recipients.…”

Section: Introductionmentioning

confidence: 99%

Solid Organ Transplantation From Hepatitis B Virus–Positive Donors: Consensus Guidelines for Recipient Management

Huprikar

Danziger‐Isakov

Ahn

et al. 2015

American Journal of Transplantation

206

169

View full text Add to dashboard Cite

Use of organs from donors testing positive for hepatitis B virus (HBV) may safely expand the donor pool. The American Society of Transplantation convened a multidisciplinary expert panel that reviewed the existing literature and developed consensus recommendations for recipient management following the use of organs from HBV positive donors. Transmission risk is highest with liver donors and significantly lower with non‐liver (kidney and thoracic) donors. Antiviral prophylaxis significantly reduces the rate of transmission to liver recipients from isolated HBV core antibody positive (anti‐HBc+) donors. Organs from anti‐HBc+ donors should be considered for all adult transplant candidates after an individualized assessment of the risks and benefits and appropriate patient consent. Indefinite antiviral prophylaxis is recommended in liver recipients with no immunity or vaccine immunity but not in liver recipients with natural immunity. Antiviral prophylaxis may be considered for up to 1 year in susceptible non‐liver recipients but is not recommended in immune non‐liver recipients. Although no longer the treatment of choice in patients with chronic HBV, lamivudine remains the most cost‐effective choice for prophylaxis in this setting. Hepatitis B immunoglobulin is not recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

Solid Organ Transplantation From Hepatitis B Virus–Positive Donors: Consensus Guidelines for Recipient Management

Huprikar

Danziger‐Isakov

Ahn

et al. 2015

American Journal of Transplantation

206

169

View full text Add to dashboard Cite

show abstract

“…To the Editor: Studies from Taiwan have reported successful heart transplantation from HBsAg-positive donors. [4][5][6] With appropriate antiviral and/ or immunoprophylaxis in HBV-naïve patients, no HBV-related morbidity or mortality was encountered. 6 In conclusion, the use of HBsAg-positive donors must be con-…”

Section: Hepatitis B Surface Antigen-positive Donor To Negative Recipmentioning

confidence: 99%

Hepatitis B surface antigen–positive donor to negative recipient lung transplantation

Belga

Kabbani

Doucette

2020

American Journal of Transplantation

View full text Add to dashboard Cite

“…28 Excellent outcomes have been observed in large series of kidney and heart transplant recipients with chronic HBV without cirrhosis who are managed with antiviral therapy alone. 29,30 Pretransplant assessment of patients with chronic hepatitis B infection Patients with CHB who require nonliver organ transplant are of special concern (Table 2). One major concern is will the underlying liver disease preclude a successful long-term outcome?…”

Section: Impact Of Transplantation On the Natural History Of Chronic mentioning

confidence: 99%

“…Most available data are from Taiwan and Korea. 29,60,61 Of at least 42 reported recipients of HBsAg-positive donor hearts, HBsAg acquisition was observed in 2 recipients. Hepatitis B virus transmission occurred in 1 of 3 anti-HBs-negative recipients, although the HBIG protocol was not completed in this patient.…”

Section: Donors With Hepatitis B Surface Antigen Positivitymentioning

confidence: 99%

Untitled

Marzio

Fenkel²,

Doria³

2017

Exp Clin Transplant

View full text Add to dashboard Cite

Transplant is often the best treatment available for patients with end-stage organ failure. Hepatitis B virus infection in transplant procedures other than liver is a major concern because it can be a significant cause of morbidity and mortality after transplant. Due to the increased risk of hepatic complications, such as fibrosing cholestatic hepatitis or histologic deterioration after transplant, systematic use of nucleoside or nucleotide analogues shortly before or at the time of transplant is recommended (tenofovir or entecavir are preferable to lamivudine) in all patients, whatever the baseline histologic evaluation. Sustained viral suppression may result in regression of fibrosis, which in turn may lead to decreased disease-related morbidity and improved survival. Finally, due to the high mortality after nonliver transplant procedures, decompensated cirrhosis from chronic hepatitis B should be considered as a contraindication to nonliver transplant but an indication to combined organ transplant (ie, liver-kidney transplant). Because of the high prevalence of hepatitis B virus exposure in allograft donors and recipients, hepatitis B virus status must be considered during organ allocation. Prevention of hepatitis B virus-related complications in transplant recipients starts with vaccination and donor-recipient matching.

show abstract

Twenty-four Year Single-Center Experience of Hepatitis B Virus Infection in Heart Transplantation

Cited by 26 publications

References 8 publications

Solid Organ Transplantation From Hepatitis B Virus–Positive Donors: Consensus Guidelines for Recipient Management

Solid Organ Transplantation From Hepatitis B Virus–Positive Donors: Consensus Guidelines for Recipient Management

Hepatitis B surface antigen–positive donor to negative recipient lung transplantation

Untitled

Contact Info

Product

Resources

About